PARP inhibitor in Ca Ovary | PPT
PARP Inhibitors. - ppt download
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study - Gynecologic Oncology
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Efficacy | ZEJULA (niraparib) for HCPs
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Efficacy | ZEJULA (niraparib) for HCPs
Inhibidores de PARP en primera línea de cáncer de ovario | PPT
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer | Targeted Oncology
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study | Future Oncology
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count : results from the PRIMA/ENGOT-OV26/GOG-3012 trial
The latest clinical evidence on PARP inhibitor maintenance therapy - ppt download
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
First-line niraparib is associated with improvement in QA-PFS and QA-TWiST
Safety and management of niraparib monotherapy in ovarian cancer clinical trials | International Journal of Gynecologic Cancer
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
